Company Overview - Emperor International Investment Limited is a Hong Kong-listed company focused on precision oncology and genetic testing [2] - The company provides molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, high-risk health individuals, and researchers in cancer-related fields [2] - The company has developed genetic testing products covering various types of tumors, including respiratory, digestive, breast, gynecological, urinary, and head and neck tumors, facilitating early screening, auxiliary diagnosis, medication guidance, prognosis assessment, and dynamic monitoring throughout the cancer management process [2] Financial Performance - As of September 30, 2024, Emperor International Investment reported total revenue of 33.534 million yuan, a year-on-year decrease of 55.43% [1] - The company recorded a net profit attributable to the parent of -1.4311 million yuan, a year-on-year decrease of 193.74% [1] - The gross profit margin stood at 2.71%, and the debt-to-asset ratio was 21.08% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.3 times, with a median of 5.39 times [1] - Emperor International Investment has a P/E ratio of 10.33 times, ranking 28th in the industry [1] - Comparatively, other companies in the health sector have significantly lower P/E ratios, such as Great Health International at 0.56 times and King’s Ray Biotechnology at 1.25 times [1]

Group 1 - The core viewpoint of the news highlights the recent performance of Emperor International Investment, which has seen a significant decline in its stock price and financial metrics, indicating potential challenges ahead for the company [2][3]. - As of April 2, the Hang Seng Index closed at 23,202.53 points, down 0.02%, while Emperor International Investment's stock price increased by 7.41% to HKD 0.029 per share, with a trading volume of 2.2 million shares [1]. - Over the past month, Emperor International Investment has experienced a cumulative decline of 10%, and a year-to-date decline of 40%, underperforming the Hang Seng Index by 15.69% [2]. Group 2 - Financial data shows that as of September 30, 2024, Emperor International Investment reported total revenue of HKD 33.534 million, a decrease of 55.43% year-on-year, and a net profit attributable to the parent company of -HKD 1.4311 million, down 193.74% year-on-year [2]. - The company's gross profit margin stands at 2.71%, with a debt-to-asset ratio of 21.08% [2]. - Currently, there are no institutional investment ratings for Emperor International Investment, and its price-to-earnings (P/E) ratio is 3.98, ranking fifth in the industry, which has an average P/E ratio of 12.42 [3]. Group 3 - Emperor International Investment is a Hong Kong-listed company focused on precision oncology and genetic testing, providing molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, and high-risk health groups [4]. - The company has developed genetic testing products for various types of tumors, including respiratory, digestive, breast, gynecological, urinary, and head and neck tumors, covering all stages of cancer management from early screening to dynamic monitoring [4]. - The company operates laboratories in Beijing and Guangzhou, adhering to strict quality management standards and achieving high scores in various assessments [4].

潮水退去。 一声叹息。 作者 I 王露 报道 I 投资界PEdaily 本周，基因检测鼻祖2 3 a ndMe宣布，已申请美国破产法11章破产保护。至此，又一明星独角兽轰然陨落。 1 9年前，2 3 a n dMe含着金汤匙诞生——创始人安妮·沃西基被称为"女版乔布斯"，让DNA检测风靡一时。公司融资路上更是开挂一举融 到F轮，身后集结了谷歌、Se qu o i a Ca p it a l（红杉资本）以及强生、药明康德等一众巨头，最后借助SPAC上市，市值一度高达6 0亿美 元。 然而时过境迁，盛宴终散场。2 3 a n dMe的陨落再次给当下千千万万创业公司敲响警钟——依赖融资烧钱，没有造血能力，最终只能关 门收场。 市值曾400亿 一个医疗独角兽倒下了 故事得从创始人An n e Woj c i c k i（安妮·沃西基）说起。 安妮出生于1 9 7 3年，在斯坦福长大，父亲是著名物理学家。身为女孩却热爱激烈的冰球运动，安妮从小就不服输，这与她的高知家庭 密不可分。 吐一管唾液，寄给2 3 a n dMe，就能得到一份DNA报告，包括祖先来自何处、中年秃顶或患阿兹海默症的可能性等。彼时，基因检测是 实验室 ...